Increasing Prevelance of Leishmaniasis to propel growth of the Leishmaniasis Treatment Market
 |
| Leishmaniasis Treatment Market |
Market
Overview:
Leishmaniasis
is a vector-borne parasitic disease caused by protozoan parasites of the genus
Leishmania. It is transmitted by the bite of infected female phlebotomine sand
flies. The disease causes a wide variety of clinical symptoms, the most common
being cutaneous and visceral leishmaniasis. There are several treatment options
available for leishmaniasis including pentavalent antimonials, miltefosine,
paromomycin, and amphotericin B. While these drugs are used as first line
therapies, resistance has increased considerably. Hence, there is significant need
for safe and effective treatment options against leishmaniasis.
Market key trends:
One of the key trends in the Leishmaniasis
Treatment Market Demand is growing preference for combination therapies
over monotherapies. Combination therapies involve use of two or more
antileishmanial drugs simultaneously that helps in decreasing treatment
duration and prevents development of drug resistance. For instance, combination
of sodium stibogluconate and paromomycin is recommended as first line treatment
for visceral leishmaniasis. Moreover, several pipeline drugs are combination
therapies as they provide higher cure rates compared to conventional
monotherapy regimens. Furthermore, rising investment by pharmaceutical
companies in R&D of novel drug candidates is also contributing to market
growth. For example, new oral drug candidates such as AN3807, DL1900 and OZP091
are being developed to offer safer and more effective treatment options for
leishmaniasis patients.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate due to high
capital requirements for R&D and manufacturing in pharmaceutical industry.
Bargaining power of buyers: The bargaining power of buyers is low as standard
treatment options are limited and buyers have less influence over prices.
Bargaining power of suppliers: Suppliers have moderate power due to
availability of alternative suppliers and less differentiation in raw
materials.
Threat of new substitutes: Threat of new substitutes is low as alternative
treatment options are very limited for leishmaniasis disease currently.
Competitive rivalry: Competition is high among existing players to gain higher
market share.
Key Takeaways
The global leishmaniasis treatment market size is expected to reach US$
69.4 Million by 2030, exhibiting a CAGR of 4.4% over the forecast period.
Increasing prevalence of leishmaniasis disease globally is majorly driving the
market.
Regional analysis: North America region currently dominates the leishmaniasis
treatment market and is expected to continue its dominance owing to growing
research activities for leishmaniasis treatment. However, Asia Pacific region
is anticipated to witness fastest growth during the forecast period attributed
to rising cases of leishmaniasis disease in developing countries such as India
and China.
Key players: Key players operating in the leishmaniasis treatment market are
Knight Therapeutics, gland pharma, Sanofi, Novartis, GloxoSmithKline, Pfizer,
Cheplapharm Arzneimittel GmbH and Jassen Pharmaceutical. These players are
focusing on development and commercialization of advanced treatment options to
gain competitive edge in the market.
Read More
Comments
Post a Comment